Cancer is a deadly killer that has been affecting families globally for far too long. Despite billions of dollars placed into research, there has not been a great amount of success in helping victim’s survive the tragic battle. One company in Maryland has developed a vaccine to stimulate a patient’s own immune system to fight cancer. That company is Northwest Biotherapeutics; their vaccine is the DCVaxA-Brain.

The DCVaxA-Brain is a groundbreaking vaccine because it is made up of the patient’s own “dendritic cells”, master cells that direct the immune system. The “dendritic cells” have been activated and educated to mobilize the whole immune system to recognize and destroy cancer cells bearing the biomarkers of the patients own tumor.

Today, Northwest Biotherapeutics announced further long-term data for the period from January through September of 2009 from its prior Phase I and Phase I/II clinical trials conducted at UCLA with

...

Leading DNA vaccine discovery company, Inovio Biomedical Corporation announced that their Scientific Advisory Board Chairman, Dr. David B. Weiner, highlighted advances in the company’s leading electroporation-delivered SynCon™ DNA vaccines at the AIDS Vaccine 2009 Conference in Paris.

The study, led by Dr. Weiner’s team at the University of Pennsylvania, included collaborators from Inovio and Merck. The team previously reported that DNA vaccines delivered using electroporation induced dramatic increases in T-cell and antibody-based immune responses. This collaborative study was the first to directly compare a DNA plasmid-electroporation platform with a recombinant Ad5 vector in an SIV model in non-human primates.

Dr. Weiner presented pre-clinical data showing higher levels of immune responses induced by Inovio’s DNA vaccines than to those induced by the recombinant adenovirus serotype 5 (Ad5) vector. Historically, recombinant Ad5 vector has been shown to be one of the most potent viral vectors for vaccines.

In his presentation, Dr. Weiner also

...

Baxter International Inc. (BAX) recently received marketing authorization for CELVAPAN H1N1 vaccine, commonly known as the Swine Flu vaccine, in the European Union. The company has already delivered limited quantities of H1N1 vaccine to a few countries, such as the UK and Ireland, as part of their national vaccination programs. Presently, Baxter is conducting two clinical trials to confirm the safety and immunogenicity of CELVAPAN H1N1. These trials encompass 400 healthy adults who are 18 years and above, besides 400 children and adolescents. The safety and immunogenicity of CELVAPAN H1N1 in these trials are conducted at dose levels of 7.5µg and 3.75µg, respectively. Baxter also plans to conduct a large-scale study of CELVAPAN in 9,000 people of different age groups including children. Preliminary safety data in adults for 7.5µg doses of vaccine indicated that the vaccine was well tolerated in these age groups. The reactions were ...

Yesterday, Dynavax Technologies Corp. (DVAX) announced that it has resumed the late-stage registration trial of its hepatitis B (HBV) vaccine Heplisav in patients with chronic kidney disease. The trial will enroll 600 patients. Heplisav will be tested against GlaxoSmithKline plc’s (GSK) Engerix-B. The company intends to begin another late-stage registration trial in adults over 40 years of age in early 2010. Dynavax expects to complete both trials within the next 2 years. Management expects the vaccine to hit the market by the end of 2012 or early 2013.   As a reminder, Heplisav was on clinical hold in the U.S since March 17, 2008 following the occurrence of the severe adverse event (SAE) of Wegener's granulomatosis. The SAE was reported in the phase III study in healthy adults conducted outside the US. Wegener's granulomatosis is an uncommon disease which results in the inflammation of blood vessels. ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 23, 2009

DrStockPick.com Stock Report!

PWRM, RTN, CVAT, LMT, CSRH, INTU, TSPG, MRK, QGEN

**************************************************************

RTN, Raytheon Company

RTN is a technology and innovation leader specializing in defense, homeland security and other government markets throughout the world.

RTN has surpassed another milestone on its Modernized User Equipment program by achieving live satellite M-code tracking with its MUE receiver. A Raytheon-led team developed modernized versions of the avionics and the ground-based module that receives signals from the Global Positioning System. Delivery of the pre-production receiver to the government is expected in November 2009.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is

...

Target Corporation (TGT) recently announced that with effect from October 2009, flu vaccinations would be readily available at over 1,500 Target Pharmacy locations nationwide. The vaccination program will begin on Oct 3, 2009, and run through Nov 7, 2009. The cost of flu vaccines starts at only $24.  Target accepts various insurance plans so that the people do not have to bear the cost of vaccinations. These vaccines do not safeguard against the deadly H1N1 flu, but are essential to protect families against seasonal flu and are recommended by Centers for Disease Control and Prevention.  Local, state and federal health authorities are currently administering the production and distribution of the H1N1 vaccine. More than 200,000 people suffer from seasonal flu in the U.S. every year.  The target group falls within the age bracket of 6 months to 19 years and 50 years or above, pregnant ...

Companies featured in this edition of the newsletter: CVM, ICLK, IMUC, ITUI, IWEB, MBCI, NXOI, OMCM, ONEZ, PHC, SRCO, SVUL, XCR

Markets closed moderately higher yet again this week, as mostly better than expected economic data helped stave off profit taking to leave most indices in positive territory on the week. All told, the Dow ended the week up 0.4%, closing at 9544, up 38 points, bringing its YTD gains to 8.7%. The Nasdaq also gained 0.4% on the week to close at 2028, bringing its yearly gains to 28.6%, while the S&P 500 gained 0.3% and the Russell 2000 lost 0.3%, bringing their yearly gains to 13.9% and 16.1% respectively.

Economic news was in focus yet again this week in the absence of any market driving earnings data, as new home sales for July rose at 9.6%, posting its strongest gains since 2005. This positive development coupled with

...

Companies featured in this edition of the newsletter: CVM, ICLK, IMUC, ITUI, IWEB, MBCI, NXOI, OMCM, ONEZ, PHC, SRCO, SVUL, XCR

Markets closed moderately higher yet again this week, as mostly better than expected economic data helped stave off profit taking to leave most indices in positive territory on the week. All told, the Dow ended the week up 0.4%, closing at 9544, up 38 points, bringing its YTD gains to 8.7%. The Nasdaq also gained 0.4% on the week to close at 2028, bringing its yearly gains to 28.6%, while the S&P 500 gained 0.3% and the Russell 2000 lost 0.3%, bringing their yearly gains to 13.9% and 16.1% respectively.

Economic news was in focus yet again this week in the absence of any market driving earnings data, as new home sales for July rose at 9.6%, posting its strongest gains since 2005. This positive development coupled with

...

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced this morning that it has executed a Material Transfer Agreement (MTA) with Archimedes Development Limited. This collaboration enables the companies to identify possible synergies between their technology platforms.

“Multiple studies in different model systems have shown that Homspera can protect experimental animals and enhance their immune responses to vaccine-delivered antigens, DNA-encoded viral proteins or tumor antigens, as well as provide protection in our anthrax and influenza therapeutic studies,” stated Hal Siegel, Ph.D., ImmuneRegen’s Vice President and Chief Scientific Officer.

He continued, “In addition to these findings in animals where Homspera has been administered intranasally as a liquid, inhaled or injected under the skin, we have shown in laboratory studies that Homspera can stimulate blood-forming stem cells to produce more white blood cell precursors, particularly those for granulocytes and macrophages, mature blood cells which play a significant role in

...

Companies featured in this edition of the newsletter: CUR, CVM, DKAM, ICLK, IMUC, IWEB, OMCM, ONEZ, SVUL, TAGS

Markets managed to extend their run this week, hitting fresh highs for ‘09 despite coming under pressure from negative economic reports and a significant two week correction in Chinese equity markets. All told, the Dow ended up 2.0%, gaining 184 points to close at 9505, extending its yearly gains to 8.3%. The Nasdaq finished the week up 1.8%, closing back above 2000 at 2020, up 28.1% on the year, while the S&P 500 and Russell 2000 managed to post gains of 2.2% and 3.1% respectively, bringing their yearly gains to 13.6% and 16.4%.

Concerns stemming from weakness in Chinese markets which have surrendered 20% in the past two weeks after climbing 109% from October lows spooked many investors expecting a similar correction in US markets early in the week. US

...